182 related articles for article (PubMed ID: 1687773)
21. Pharmacological effects of nalorphine and nalorphine-7,8-oxide (nalorphine-epoxide): interaction of the intrinsic activity, affinity and pharmacological responses.
Konno F; Kobayashi C; Morimoto R; Takayanagi I; Cho N; Hirobe M
Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):219-32. PubMed ID: 2876689
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of dynorphin-(1-8) in isolated preparations by three peptidases.
Numata H; Hiranuma T; Oka T
Jpn J Pharmacol; 1988 Aug; 47(4):417-23. PubMed ID: 2903264
[TBL] [Abstract][Full Text] [Related]
23. Dynorphin-(1-13). I. Structure-function relationships of Ala-containing analogs.
Turcotte A; Lalonde JM; St-Pierre S; Lemaire S
Int J Pept Protein Res; 1984 Apr; 23(4):361-7. PubMed ID: 6327549
[TBL] [Abstract][Full Text] [Related]
24. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
[TBL] [Abstract][Full Text] [Related]
25. In vitro study of the interaction of salmon calcitonin with mu, delta and kappa opioid agonists.
MartÃn MI; Alfaro MJ; Goicoechea C; Colado MI
Naunyn Schmiedebergs Arch Pharmacol; 1993 Mar; 347(3):324-8. PubMed ID: 8386807
[TBL] [Abstract][Full Text] [Related]
26. 125I-DPDYN, monoiodo [D-Pro10]- dynorphin (1-11), is an effective and useful tool for the study of kappa opioid receptors.
Gairin JE; Jomary C; Cros J; Meunier JC
NIDA Res Monogr; 1986; 75():232-5. PubMed ID: 2893266
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological activity of analogs of dynorphin-A(1-13) substituted in positions 2 and 4: design of [Ala2,Trp4]-Dyn-A(1-13) as a putative selective opioid antagonist.
Lemaire S; Turcotte A
Can J Physiol Pharmacol; 1986 Jun; 64(6):673-8. PubMed ID: 2875777
[TBL] [Abstract][Full Text] [Related]
28. Opioid receptors for the dynorphin peptides.
James IF
NIDA Res Monogr; 1986; 70():192-208. PubMed ID: 2876385
[No Abstract] [Full Text] [Related]
29. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
[TBL] [Abstract][Full Text] [Related]
30. Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with beta-funaltrexamine.
Ward SJ; LoPresti D; James DW
J Pharmacol Exp Ther; 1986 Aug; 238(2):625-31. PubMed ID: 3016244
[TBL] [Abstract][Full Text] [Related]
31. Dynorphin B-29: chemical synthesis and pharmacological properties in opioid systems in vitro.
Sanchez-Blazquez P; Chang JK; Garzon J; Lee NM
Neuropeptides; 1984 Sep; 4(5):369-74. PubMed ID: 6149489
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of highly potent and selective cyclic dynorphin A analogues.
Kawasaki AM; Knapp RJ; Kramer TH; Wire WS; Vasquez OS; Yamamura HI; Burks TF; Hruby VJ
J Med Chem; 1990 Jul; 33(7):1874-9. PubMed ID: 1972964
[TBL] [Abstract][Full Text] [Related]
33. [Preferential action of eptazocine, a novel analgesic, with opioid receptors in isolated guinea pig ileum and mouse vas deferens preparations].
Tamura T; Ogawa J; Taniguchi T; Waki I
Nihon Yakurigaku Zasshi; 1990 Jan; 95(1):41-6. PubMed ID: 2154395
[TBL] [Abstract][Full Text] [Related]
34. The choice of opioid receptor subtype in isolated preparations by ohmefentanyl.
Jin WQ; Chen XJ; Chi ZQ
Sci Sin B; 1987 Feb; 30(2):176-81. PubMed ID: 3039656
[TBL] [Abstract][Full Text] [Related]
35. N,N-diallyl-tyrosyl substitution confers antagonist properties on the kappa-selective opioid peptide [D-Pro10]dynorphin A(1-11).
Gairin JE; Mazarguil H; Alvinerie P; Botanch C; Cros J; Meunier JC
Br J Pharmacol; 1988 Dec; 95(4):1023-30. PubMed ID: 2905908
[TBL] [Abstract][Full Text] [Related]
36. Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations.
Kajiwara M; Aoki K; Ishii K; Numata H; Matsumiya T; Oka T
Jpn J Pharmacol; 1986 Jan; 40(1):95-101. PubMed ID: 3007830
[TBL] [Abstract][Full Text] [Related]
37. Exploration of universal cysteines in the binding sites of three opioid receptor subtypes by disulfide-bonding affinity labeling with chemically activated thiol-containing dynorphin A analogs.
Shirasu N; Kuromizu T; Nakao H; Chuman Y; Nose T; Costa T; Shimohigashi Y
J Biochem; 1999 Jul; 126(1):254-9. PubMed ID: 10393346
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
Kawasaki AM; Knapp RJ; Kramer TH; Walton A; Wire WS; Hashimoto S; Yamamura HI; Porreca F; Burks TF; Hruby VJ
J Med Chem; 1993 Mar; 36(6):750-7. PubMed ID: 8096246
[TBL] [Abstract][Full Text] [Related]
39. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
Traynor JR; Corbett AD; Kosterlitz HW
Eur J Pharmacol; 1987 May; 137(1):85-9. PubMed ID: 3038579
[TBL] [Abstract][Full Text] [Related]
40. A novel opioid peptide, leumorphin, acts as an agonist at the kappa opiate receptor.
Suda M; Nakao K; Yoshimasa T; Ikeda Y; Sakamoto M; Yanaihara N; Numa S; Imura H
Life Sci; 1983 Jun; 32(24):2769-75. PubMed ID: 6134225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
